Vaccinex (VCNX) Stock Price, News & Analysis

Company Overview

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Key Stats

• Today's Range: $3.52 to $3.75
• 50-Day Range: $1.73 to $6.00
• 52-Week Range: $1.39 to $13.02
• Volume: 25,685 shs
• Average Volume: 55,163 shs
• Market Capitalization: $9.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Vaccinex Stock Analysis - MarketRank™

Vaccinex scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Vaccinex.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Vaccinex is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vaccinex is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.11% of the float of Vaccinex has been sold short.

Short Interest Ratio / Days to Cover

Vaccinex has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vaccinex has recently increased by 269.57%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vaccinex does not currently pay a dividend.

Dividend Growth

Vaccinex does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.11% of the float of Vaccinex has been sold short.

Short Interest Ratio / Days to Cover

Vaccinex has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vaccinex has recently increased by 269.57%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.67

News Sentiment

Vaccinex has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Vaccinex this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for VCNX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vaccinex insiders have not sold or bought any company stock.

Percentage Held by Insiders

51.50% of the stock of Vaccinex is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

50.11% of the stock of Vaccinex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VCNX Stock Analysis - Frequently Asked Questions

How have VCNX shares performed this year?

Vaccinex's stock was trading at $9.3072 at the start of the year. Since then, VCNX shares have decreased by 61.1% and is now trading at $3.62.
View the best growth stocks for 2024 here.

How were Vaccinex's earnings last quarter?

Vaccinex, Inc. (NASDAQ:VCNX) issued its quarterly earnings data on Monday, November, 8th. The company reported ($35.70) earnings per share for the quarter, beating the consensus estimate of ($60.90) by $25.20. The company earned $0.05 million during the quarter.

When did Vaccinex's stock split?

Vaccinex shares reverse split before market open on Tuesday, February 20th 2024. The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Vaccinex IPO?

Vaccinex (VCNX) raised $45 million in an IPO on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

Who are Vaccinex's major shareholders?

Top institutional investors of Vaccinex include Point72 Asset Management L.P. (9.60%). Insiders that own company stock include Albert Friedberg, Maurice Zauderer, Strydonck Gerald E Van and Jacob B Frieberg.
View institutional ownership trends.

How do I buy shares of Vaccinex?

Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Vaccinex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vaccinex investors own include Pfizer (PFE), VBI Vaccines (VBIV), OPKO Health (OPK), Plug Power (PLUG), Vaxart (VXRT), NIO (NIO) and SNDL (SNDL).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 11/23/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VCNX
• CUSIP: N/A
• CIK: 1205922
• Web: www.vaccinex.com
• Phone: (585) 271-2700
• Fax: 585-271-2765
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($48.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-20,250,000.00
• Net Margins: N/A
• Pretax Margin: -4,787.89%
• Return on Equity: N/A
• Return on Assets: -383.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.77
• Quick Ratio: 0.77

Sales & Book Value

• Annual Sales: $388,000.00
• Price / Sales: 24.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.65) per share
• Price / Book: -2.19

Miscellaneous

• Outstanding Shares: 2,600,000
• Free Float: 838,000
• Market Cap: $9.41 million
• Optionable: No Data
• Beta: 0.98